

# David Hedley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7814376/publications.pdf>

Version: 2024-02-01

79  
papers

6,130  
citations

101384

36  
h-index

74018

75  
g-index

82  
all docs

82  
docs citations

82  
times ranked

12403  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Definitive Chemoradiation on the Quality of Life Changes for Anal Cancer Patients. <i>Diseases of the Colon and Rectum</i> , 2022, Publish Ahead of Print, .	0.7	0
2	An Iodinated DAPI-Based Reagent for Mass Cytometry. <i>ChemBioChem</i> , 2021, 22, 532-538.	1.3	2
3	Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, <sup>111</sup> In or <sup>β</sup> -particle emitting, <sup>177</sup> Lu. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020, 5, 22.	1.8	10
4	Tumor Platinum Concentrations and Pathological Responses Following Cisplatin-Containing Chemotherapy in Gastric Cancer Patients. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 801-807.	0.6	9
5	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019, 49, 1457-1973.	1.6	766
6	Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1195-1200.	1.1	4
7	Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. <i>Cancer Cell</i> , 2019, 35, 267-282.e7.	7.7	151
8	Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer. <i>PLoS Computational Biology</i> , 2019, 15, e1006596.	1.5	51
9	Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. <i>Clinical Cancer Research</i> , 2018, 24, 1344-1354.	3.2	414
10	Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. <i>Clinical Colorectal Cancer</i> , 2018, 17, 73-79.	1.0	17
11	The ongoing challenge of large anal cancers: prospective long term outcomes of intensity-modulated radiation therapy with concurrent chemotherapy. <i>Oncotarget</i> , 2018, 9, 20439-20450.	0.8	21
12	EGFR-Targeted Metal Chelating Polymers (MCPs) Harboring Multiple Pendant PEG2K Chains for MicroPET/CT Imaging of Patient-Derived Pancreatic Cancer Xenografts. <i>ACS Biomaterials Science and Engineering</i> , 2017, 3, 279-290.	2.6	7
13	Staining of Frozen and Formalin-Fixed, Paraffin-Embedded Tissues with Metal-Labeled Antibodies for Imaging Mass Cytometry Analysis. <i>Current Protocols in Cytometry</i> , 2017, 82, 12.47.1-12.47.8.	3.7	23
14	Guidelines for the use of flow cytometry and cell sorting in immunological studies <sup>*</sup> . <i>European Journal of Immunology</i> , 2017, 47, 1584-1797.	1.6	505
15	Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. <i>JAMA Oncology</i> , 2017, 3, 774.	3.4	221
16	Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts. <i>British Journal of Cancer</i> , 2017, 116, 50-57.	2.9	22
17	Long term responders to palliative chemotherapy for advanced biliary tract cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 352-360.	0.6	12
18	Cancer initiating-cells are enriched in the CA9 positive fraction of primary cervix cancer xenografts. <i>Oncotarget</i> , 2017, 8, 1392-1404.	0.8	9

#	ARTICLE	IF	CITATIONS
19	A phase I study of elesclomol sodium in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2437-2440.	0.6	40
20	Isotopologous Organotellurium Probes Reveal Dynamic Hypoxia In Vivo with Cellular Resolution. <i>Angewandte Chemie</i> , 2016, 128, 13353-13357.	1.6	9
21	Isotopologous Organotellurium Probes Reveal Dynamic Hypoxia In Vivo with Cellular Resolution. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 13159-13163.	7.2	32
22	Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 994-1002.	0.4	3
23	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCIâ™9041). <i>Investigational New Drugs</i> , 2016, 34, 104-111.	1.2	17
24	Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers. <i>Journal of Clinical Pathology</i> , 2016, 69, 695-701.	1.0	10
25	Cytokinetic effects of Wee1 disruption in pancreatic cancer. <i>Cell Cycle</i> , 2016, 15, 593-604.	1.3	10
26	Outcome of Adjuvant Therapy in Biliary Tract Cancers. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 382-387.	0.6	36
27	Whole Blood Measurement of Histone Modifications Linked to the Epigenetic Regulation of Gene Expression. <i>Current Protocols in Cytometry</i> , 2015, 71, 6.36.1-6.36.9.	3.7	1
28	The Clinical Significance of Hypoxia in Human Cancers. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 110-121.	2.5	166
29	Germline <i>BRCA</i> Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3124-3129.	0.8	324
30	Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle. <i>Journal of Controlled Release</i> , 2015, 206, 122-130.	4.8	106
31	Identification of Hypoxic Cells Using an Organotellurium Tag Compatible with Mass Cytometry. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 11473-11477.	7.2	37
32	Assessment of Hypoxia in the Stroma of Patient-Derived Pancreatic Tumor Xenografts. <i>Cancers</i> , 2014, 6, 459-471.	1.7	57
33	The study of epigenetic mechanisms based on the analysis of histone modification patterns by flow cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2014, 85, 78-87.	1.1	24
34	Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study. <i>European Journal of Cancer</i> , 2013, 49, 329-335.	1.3	104
35	Response to letter â€œOutcome of second-line chemotherapy for biliary tract cancerâ€™. <i>European Journal of Cancer</i> , 2013, 49, 1512-1513.	1.3	1
36	Abstract 4647: Tie2-expressing monocytes (TEMs) as potential biomarkers of angiopoietin-Tie2 (Ang/Tie2) directed therapies: correlative analysis of a phase I study of AMG386 + temsirolimus (T).., 2013, , .		1

#	ARTICLE	IF	CITATIONS
37	Molecular application of spectral photoacoustic imaging in pancreatic cancer pathology. Proceedings of SPIE, 2012, , .	0.8	0
38	Emerging applications of flow cytometry in solid tumor biology. Methods, 2012, 57, 359-367.	1.9	24
39	Hedgehog pathway signaling in cervical carcinoma and outcome after chemoradiation. Cancer, 2012, 118, 3105-3115.	2.0	50
40	A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Investigational New Drugs, 2012, 30, 1203-1207.	1.2	22
41	A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Investigational New Drugs, 2012, 30, 779-786.	1.2	49
42	Integration of experimental facilities: A joint effort for establishing a common knowledge base in experimental work on hydrogen safety. International Journal of Hydrogen Energy, 2011, 36, 2700-2710.	3.8	7
43	Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy. Journal of Clinical Oncology, 2011, 29, 2077-2084.	0.8	95
44	A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 609-613.	0.6	61
45	A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leukemia and Lymphoma, 2010, 51, 252-260.	0.6	85
46	Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. Cancer Biology and Therapy, 2009, 8, 1893-1901.	1.5	28
47	Heterogeneity and Power in Clinical Biomarker Studies. Journal of Clinical Oncology, 2009, 27, 1517-1521.	0.8	30
48	Gene Expression Profiling of Adenosine Triphosphate-Binding Cassette Transporters in Response to K-ras Activation and Hypoxia in Human Pancreatic Cancer Cell Cultures. Pancreas, 2009, 38, 85-93.	0.5	4
49	Antileukemic Effects of the Novel Agent Elesclomol.. Blood, 2009, 114, 2736-2736.	0.6	3
50	A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Research and Treatment, 2008, 108, 87-92.	1.1	73
51	Whole Blood Processing for Measurement of Signaling Proteins by Flow Cytometry. Current Protocols in Cytometry, 2008, 46, Unit 9.27.	3.7	8
52	Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib. Journal of Clinical Oncology, 2007, 25, 2184-2190.	0.8	92
53	Dissociation of Gemcitabine Sensitivity and Protein Kinase B Signaling in Pancreatic Ductal Adenocarcinoma Models. Pancreas, 2007, 35, e16-e26.	0.5	13
54	Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: A phase I-II study. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1027-1036.	0.4	41

#	ARTICLE	IF	CITATIONS
55	The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. <i>Human Genetics</i> , 2007, 121, 635-637.	1.8	40
56	Potentiated Phospho-Protein Network Profiling of Multiple Myeloma Cell Lines and Primary Patient Samples by Multi-Parameter Flow Cytometry.. <i>Blood</i> , 2007, 110, 1505-1505.	0.6	0
57	Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. <i>Cytometry Part B - Clinical Cytometry</i> , 2006, 70B, 107-114.	0.7	49
58	Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2005, 67A, 4-17.	1.1	111
59	Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 2332-2338.	0.8	297
60	A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5526-5533.	3.2	99
61	Raf kinase as a target for anticancer therapeutics. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 677-685.	1.9	235
62	The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors. <i>Clinical Cancer Research</i> , 2005, 11, 8782-8788.	3.2	428
63	Carbonic Anhydrase IX as a Marker for Poor Prognosis in Soft Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2004, 10, 4464-4471.	3.2	76
64	Phase II Study of Activated Charcoal to Prevent Irinotecan-Induced Diarrhea. <i>Journal of Clinical Oncology</i> , 2004, 22, 4410-4417.	0.8	70
65	The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. <i>Seminars in Radiation Oncology</i> , 2004, 14, 249-258.	1.0	140
66	Up-Regulation of the Redox Mediators Thioredoxin and Apurinic/Apyrimidinic Excision (APE)/Ref-1 in Hypoxic Microregions of Invasive Cervical Carcinomas, Mapped Using Multispectral, Wide-Field Fluorescence Image Analysis. <i>American Journal of Pathology</i> , 2004, 164, 557-565.	1.9	44
67	NKIAMRE, a novel conserved CDC2-related kinase with features of both mitogen-activated protein kinases and cyclin-dependent kinases. <i>Biochemical and Biophysical Research Communications</i> , 2003, 308, 784-792.	1.0	20
68	Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. <i>Clinical Cancer Research</i> , 2003, 9, 5666-74.	3.2	95
69	A comparison in individual murine tumors of techniques for measuring oxygen levels. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 44, 1137-1146.	0.4	50
70	A phase II study of temozolomide in advanced untreated pancreatic cancer. <i>Investigational New Drugs</i> , 1998, 16, 77-79.	1.2	24
71	Heterogeneity of tumor oxygenation: relationship to tumor necrosis, tumor size, and metastasis. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 42, 717-721.	0.4	54
72	Flow Cytometric Measurement of Intracellular pH. <i>Current Protocols in Cytometry</i> , 1997, 00, Unit 9.3.	3.7	20

#	ARTICLE	IF	CITATIONS
73	Flow cytometric determination of glutathione in clinical samples. <i>Cytometry</i> , 1995, 21, 68-71.	1.8	20
74	Chapter 3 Glutathione and Cellular Resistance to Anti-Cancer Drugs. <i>Methods in Cell Biology</i> , 1994, 42 Pt B, 31-44.	0.5	19
75	Flow cytometric measurement of lipid peroxidation in vital cells using parinaric acid. <i>Cytometry</i> , 1992, 13, 686-692.	1.8	87
76	Relationship between cytoplasmic pH and proliferation during exponential growth and cellular quiescence. <i>Experimental Cell Research</i> , 1987, 172, 65-75.	1.2	97
77	Flow cytometric measurement of cytoplasmic pH: A critical evaluation of available fluorochromes. <i>Cytometry</i> , 1986, 7, 347-355.	1.8	124
78	Modulation of transferrin receptor expression by inhibitors of nucleic acid synthesis. <i>Journal of Cellular Physiology</i> , 1985, 124, 61-66.	2.0	19
79	Integration of Genomic and Transcriptomic Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0